AngioDynamics, Inc. (ANGO): Price and Financial Metrics

AngioDynamics, Inc. (ANGO): $25.62

0.29 (+1.14%)

POWR Rating

Component Grades














  • ANGO scores best on the Growth dimension, with a Growth rank ahead of 93.91% of US stocks.
  • The strongest trend for ANGO is in Quality, which has been heading up over the past 31 weeks.
  • ANGO's current lowest rank is in the Momentum metric (where it is better than 15.14% of US stocks).

ANGO Stock Summary

  • With a one year PEG ratio of 1.21, Angiodynamics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 6.73% of US stocks.
  • Price to trailing twelve month operating cash flow for ANGO is currently 61.63, higher than 92.56% of US stocks with positive operating cash flow.
  • Over the past twelve months, ANGO has reported earnings growth of -475.46%, putting it ahead of just 4.19% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Angiodynamics Inc are EPM, CULP, INTZ, TORM, and DOGZ.
  • Visit ANGO's SEC page to see the company's official filings. To visit the company's web site, go to

ANGO Price Target

For more insight on analysts targets of ANGO, see our ANGO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.50 Average Broker Recommendation 1.67 (Moderate Buy)

ANGO Stock Price Chart Interactive Chart >

Price chart for ANGO

ANGO Price/Volume Stats

Current price $25.62 52-week high $25.75
Prev. close $25.33 52-week low $8.05
Day low $25.13 Volume 83,065
Day high $25.66 Avg. volume 285,213
50-day MA $24.02 Dividend yield N/A
200-day MA $17.73 Market Cap 977.07M

AngioDynamics, Inc. (ANGO) Company Bio

AngioDynamics designs, manufactures, and sells various medical, surgical, and diagnostic devices for vascular access, surgery, peripheral vascular disease, and oncology in the United States and internationally. The company was founded in 1988 and is based in Latham, New York.

ANGO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$25.62$1.07 -95%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Angiodynamics Inc. To summarize, we found that Angiodynamics Inc ranked in the 8th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Angiodynamics Inc, consider:

  • The compound growth rate in the free cash flow of Angiodynamics Inc over the past 5.64 years is -0.07%; that's higher than only 14.65% of free cash flow generating stocks in the Healthcare sector.
  • Angiodynamics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -186.73. This coverage rate is greater than that of only 1.04% of stocks we're observing for the purpose of forecasting via discounted cash flows.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ANGO, try PAHC, ATRS, DYNT, PRGO, and ALC.

ANGO Latest News Stream

Event/Time News Detail
Loading, please wait...

ANGO Latest Social Stream

Loading social stream, please wait...

View Full ANGO Social Stream

Latest ANGO News From Around the Web

Below are the latest news stories about Angiodynamics Inc that investors may wish to consider to help them evaluate ANGO as an investment opportunity.

AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System

AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.

Yahoo | June 9, 2021

AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the AlphaVac Mechanical Thrombectomy System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the non-surgical removal of thrombi or emboli from the vasculature.

Yahoo | June 8, 2021

AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in

Yahoo | June 1, 2021

Who Has Been Buying AngioDynamics, Inc. (NASDAQ:ANGO) Shares?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Yahoo | May 25, 2021

AngioDynamics to Present at the UBS Virtual Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference at 12:00 p.m. ET on Tuesday, May 25, 2021.

Yahoo | May 17, 2021

Read More 'ANGO' Stories Here

ANGO Price Returns

1-mo 10.10%
3-mo 20.17%
6-mo 79.29%
1-year 149.71%
3-year 17.36%
5-year 91.62%
YTD 67.12%
2020 -4.25%
2019 -20.47%
2018 21.05%
2017 -1.42%
2016 38.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9431 seconds.